TRML
Tourmaline Bio, Inc.
$19.77
1.02
(5.44%)
| Exchange: | NASDAQ |
| Market Cap: | 507.862M |
| Shares Outstanding: | 4.135M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Sandeep C. Kulkarni | |||||
| Full Time Employees: | 74 | |||||
| Address: |
|
|||||
| Website: | https://www.tourmalinebio.com |
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Click to read more…
Revenue Segmentation
🔒 You are currently logged out
Income Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Balance Sheet
(* All numbers are in thousands)
🔒 You are currently logged out
Cash Flow Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Analyst Estimates
(* All numbers are in thousands)
